Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 189

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 189
---
39.20 per share, which are immediately exercisable upon stockholder approval and have a term
of exercise equal to five years following date of the initial exercise date. The exercise price and number of shares of Common Stock
issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting the Common Stock and the exercise price.

A
summary of outstanding warrants as of June 30, 2025 is as follows:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (in years)   Public and Private Placement Warrants   4,596   $23,000.00    3.63   February 2024 Series A Common Warrants   306    2,780.00    2.12   September 2024 Series C Common Warrants   4,088    0.80    2.71   December 2024 Common Warrants   4,203    112.20    2.98   January 2025 Common Warrants   8,193    116.40    3.02   February 2025 Pre-funded Warrants   10,787    0.002    No expiration date   February 2025 Common Warrants   127,551    39.20    4.61   Outstanding as of June 30, 2025   159,724   $707.39    4.40  

26

NOTE 10
– FAIR VALUE MEASUREMENTS

Investment
in equity securities

 On
April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a
private placement (the “Fourth PIPE Financing”), 6,250 shares of its Series D Preferred Stock to investors in exchange for
the receipt of 1,000,279 shares of the Stella Series D Preferred Stock, in which a portion of the Stella Series D Preferred Stock was
owned by a related party investor (see Note 13). The exchange of shares was in lieu of cash, the cost of which is included in investment
in equity securities on the accompanying unaudited condensed balance sheet as of June 30, 202